Month: May 2022

The US Food and Drug Administration has cleared Abbot’s Freestyle Libre 3 system for use by people with diabetes aged 4 years and older. The new system was cleared for use for both iOS and Android compatible mobile apps, enabling real-time glucose readings in contrast to the “intermittently scanned” capability of prior Libre versions. The
0 Comments
Whether it’s dealing with another yeast infection, feeling like you constantly have UTIs, or trying to figure out what your discharge means, understanding vaginal health is really important. Here, Jenna Farmer chats to the experts to help you get the lowdown ‘down there’ Whatever you might have read online about vaginal steaming or douching (seriously,
0 Comments
Time-restricted eating reduced cardiovascular risk among older breast cancer survivors, a single-group feasibility study suggests. The results show a 15% relative decline in cardiovascular risk, measured using the Framingham Risk Score, among at-risk breast cancer survivors (BCS) after only 8 weeks of following a time-restricted eating regimen, reported Amy A. Kirkham, PhD, assistant professor of kinesiology and
0 Comments
The World Health Organization has said that there is a “window” of opportunity to contain a recent monkeypox outbreak which has seen cases spread across Europe, the U.S. and Australia. Nurphoto | Nurphoto | Getty Images The World Health Organization said Monday that it is too soon to tell whether a recent monkeypox outbreak could
0 Comments
A case report published in the New England Journal of Medicine provides evidence that enterovirus D68 directly infects spinal cord neurons and that a corresponding robust immune response is present – a direct causation to the polio-like paralyzing illness, acute flaccid myelitis (AFM). Matthew Vogt, MD, PhD, assistant professor of pediatrics and microbiology & immunology
0 Comments
MILAN — Adding the cholesteryl ester transfer protein (CETP) inhibitor obicetrapib to high-intensity statins significantly lowers cholesterol levels and substantially increases the number of patients achieving cholesterol targets, suggest data from the ROSE trial. The latest results are something of a reversal for the CEPT inhibitor, after a series of disappointments led to many writing
0 Comments